Galectin-1 research in T cell immunity: Past, present and future
Abstract Galectin-1 (Gal-1) is one of 15 evolutionarily conserved ß-galactoside-binding proteins that display biologically-diverse activities in pathogenesis of inflammation and cancer. Gal-1 is variably expressed on immune cells and endothelial cells, though is commonly found and secreted at high l...
Gespeichert in:
| Veröffentlicht in: | Clinical immunology (Orlando, Fla.) Fla.), 2012-02, Vol.142 (2), p.107-116 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 116 |
|---|---|
| container_issue | 2 |
| container_start_page | 107 |
| container_title | Clinical immunology (Orlando, Fla.) |
| container_volume | 142 |
| creator | Cedeno-Laurent, Filiberto Dimitroff, Charles J |
| description | Abstract Galectin-1 (Gal-1) is one of 15 evolutionarily conserved ß-galactoside-binding proteins that display biologically-diverse activities in pathogenesis of inflammation and cancer. Gal-1 is variably expressed on immune cells and endothelial cells, though is commonly found and secreted at high levels in cancer cells. It induces apoptosis in effector T cells through homodimeric binding of N-acetyllactosamines on membrane glycoproteins (Gal-1 ligands). There is also compelling evidence in models of cancer and autoimmunity that recombinant Gal-1 (rGal-1) can potentiate immunoregulatory function of T cells. Here, we review Gal-1's structural and functional features, while analyzing potential drawbacks and technical difficulties inherent to rGal-1's nature. We also describe new Gal-1 preparations that exhibit dimeric stability and functional activity on T cells, providing renewed excitement for studying Gal-1 efficacy and/or use as anti-inflammatory therapeutics. We lastly summarize strategies targeting the Gal-1–Gal-1 ligand axis to circumvent Gal-1-driven immune escape in cancer and boost anti-tumor immunity. |
| doi_str_mv | 10.1016/j.clim.2011.09.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3266984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1521661611002804</els_id><sourcerecordid>920230821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c539t-ef15ec7ec876b4bad85b80dbe58a345c6d595a681a132b6d19af8f7286b45afd3</originalsourceid><addsrcrecordid>eNp9kstu1TAQhi0Eohd4ARbIG8SmCbYTOw5CFaiCglQJJMp65NgT6kPinNpJpfP2ODqHclmwGkv-_rn8M4Q846zkjKtXm9IOfiwF47xkbZnDA3LMpeBFwyr58PBWiqsjcpLShjEmhVCPyZHImrZp2DF5e2kGtLMPBacRE5pob6gP9JpaHAbqx3EJft69pl9Mms_odmXCTE1wtF_mJeIT8qg3Q8Knh3hKvn14f33xsbj6fPnp4t1VYWXVzgX2XKJt0OpGdXVnnJadZq5DqU1VS6ucbKVRmhteiU453ppe943QmZamd9UpOd_n3S7diM7mLqIZYBv9aOIOJuPh75_gb-D7dAeVUKrVdU7w8pAgTrcLphlGn9YhTcBpSdAKJiqmBc-k2JM2TilF7O-rcAar87CB1XlYnQfWQg5Z9PzP_u4lv6zOwIsDYJI1Qx9NsD795qRUdSNU5t7sOcxu3nmMkKzHYNH5mDcFbvL_7-P8H3lGgs8Vf-AO02ZaYsh7Ag5JAIOv642sJ8I5Y0KzuvoJN3e2uQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>920230821</pqid></control><display><type>article</type><title>Galectin-1 research in T cell immunity: Past, present and future</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Cedeno-Laurent, Filiberto ; Dimitroff, Charles J</creator><creatorcontrib>Cedeno-Laurent, Filiberto ; Dimitroff, Charles J</creatorcontrib><description>Abstract Galectin-1 (Gal-1) is one of 15 evolutionarily conserved ß-galactoside-binding proteins that display biologically-diverse activities in pathogenesis of inflammation and cancer. Gal-1 is variably expressed on immune cells and endothelial cells, though is commonly found and secreted at high levels in cancer cells. It induces apoptosis in effector T cells through homodimeric binding of N-acetyllactosamines on membrane glycoproteins (Gal-1 ligands). There is also compelling evidence in models of cancer and autoimmunity that recombinant Gal-1 (rGal-1) can potentiate immunoregulatory function of T cells. Here, we review Gal-1's structural and functional features, while analyzing potential drawbacks and technical difficulties inherent to rGal-1's nature. We also describe new Gal-1 preparations that exhibit dimeric stability and functional activity on T cells, providing renewed excitement for studying Gal-1 efficacy and/or use as anti-inflammatory therapeutics. We lastly summarize strategies targeting the Gal-1–Gal-1 ligand axis to circumvent Gal-1-driven immune escape in cancer and boost anti-tumor immunity.</description><identifier>ISSN: 1521-6616</identifier><identifier>EISSN: 1521-7035</identifier><identifier>DOI: 10.1016/j.clim.2011.09.011</identifier><identifier>PMID: 22019770</identifier><identifier>CODEN: CLIIFY</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Allergy and Immunology ; Amino Sugars - immunology ; Amino Sugars - metabolism ; Animals ; Apoptosis - immunology ; Biological and medical sciences ; Cancer immune evasion ; Carbohydrate therapeutics ; Cell Survival - immunology ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Galectin 1 - chemistry ; Galectin 1 - history ; Galectin 1 - immunology ; Galectin 1 - metabolism ; Galectin-1 ; Galectin-1 ligands ; History, 21st Century ; Humans ; Immunomodulation - immunology ; Immunoregulation ; Immunotherapy ; Inflammation - immunology ; Inflammation - metabolism ; Inflammation - therapy ; Ligands ; Lymphocyte Activation - immunology ; Mice ; Mice, Knockout ; Models, Immunological ; Neoplasms - immunology ; Neoplasms - metabolism ; Neoplasms - therapy ; Recombinant Proteins - immunology ; Recombinant Proteins - metabolism ; T-Lymphocyte Subsets - immunology ; T-Lymphocyte Subsets - metabolism</subject><ispartof>Clinical immunology (Orlando, Fla.), 2012-02, Vol.142 (2), p.107-116</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c539t-ef15ec7ec876b4bad85b80dbe58a345c6d595a681a132b6d19af8f7286b45afd3</citedby><cites>FETCH-LOGICAL-c539t-ef15ec7ec876b4bad85b80dbe58a345c6d595a681a132b6d19af8f7286b45afd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clim.2011.09.011$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25564726$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22019770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cedeno-Laurent, Filiberto</creatorcontrib><creatorcontrib>Dimitroff, Charles J</creatorcontrib><title>Galectin-1 research in T cell immunity: Past, present and future</title><title>Clinical immunology (Orlando, Fla.)</title><addtitle>Clin Immunol</addtitle><description>Abstract Galectin-1 (Gal-1) is one of 15 evolutionarily conserved ß-galactoside-binding proteins that display biologically-diverse activities in pathogenesis of inflammation and cancer. Gal-1 is variably expressed on immune cells and endothelial cells, though is commonly found and secreted at high levels in cancer cells. It induces apoptosis in effector T cells through homodimeric binding of N-acetyllactosamines on membrane glycoproteins (Gal-1 ligands). There is also compelling evidence in models of cancer and autoimmunity that recombinant Gal-1 (rGal-1) can potentiate immunoregulatory function of T cells. Here, we review Gal-1's structural and functional features, while analyzing potential drawbacks and technical difficulties inherent to rGal-1's nature. We also describe new Gal-1 preparations that exhibit dimeric stability and functional activity on T cells, providing renewed excitement for studying Gal-1 efficacy and/or use as anti-inflammatory therapeutics. We lastly summarize strategies targeting the Gal-1–Gal-1 ligand axis to circumvent Gal-1-driven immune escape in cancer and boost anti-tumor immunity.</description><subject>Allergy and Immunology</subject><subject>Amino Sugars - immunology</subject><subject>Amino Sugars - metabolism</subject><subject>Animals</subject><subject>Apoptosis - immunology</subject><subject>Biological and medical sciences</subject><subject>Cancer immune evasion</subject><subject>Carbohydrate therapeutics</subject><subject>Cell Survival - immunology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Galectin 1 - chemistry</subject><subject>Galectin 1 - history</subject><subject>Galectin 1 - immunology</subject><subject>Galectin 1 - metabolism</subject><subject>Galectin-1</subject><subject>Galectin-1 ligands</subject><subject>History, 21st Century</subject><subject>Humans</subject><subject>Immunomodulation - immunology</subject><subject>Immunoregulation</subject><subject>Immunotherapy</subject><subject>Inflammation - immunology</subject><subject>Inflammation - metabolism</subject><subject>Inflammation - therapy</subject><subject>Ligands</subject><subject>Lymphocyte Activation - immunology</subject><subject>Mice</subject><subject>Mice, Knockout</subject><subject>Models, Immunological</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - therapy</subject><subject>Recombinant Proteins - immunology</subject><subject>Recombinant Proteins - metabolism</subject><subject>T-Lymphocyte Subsets - immunology</subject><subject>T-Lymphocyte Subsets - metabolism</subject><issn>1521-6616</issn><issn>1521-7035</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kstu1TAQhi0Eohd4ARbIG8SmCbYTOw5CFaiCglQJJMp65NgT6kPinNpJpfP2ODqHclmwGkv-_rn8M4Q846zkjKtXm9IOfiwF47xkbZnDA3LMpeBFwyr58PBWiqsjcpLShjEmhVCPyZHImrZp2DF5e2kGtLMPBacRE5pob6gP9JpaHAbqx3EJft69pl9Mms_odmXCTE1wtF_mJeIT8qg3Q8Knh3hKvn14f33xsbj6fPnp4t1VYWXVzgX2XKJt0OpGdXVnnJadZq5DqU1VS6ucbKVRmhteiU453ppe943QmZamd9UpOd_n3S7diM7mLqIZYBv9aOIOJuPh75_gb-D7dAeVUKrVdU7w8pAgTrcLphlGn9YhTcBpSdAKJiqmBc-k2JM2TilF7O-rcAar87CB1XlYnQfWQg5Z9PzP_u4lv6zOwIsDYJI1Qx9NsD795qRUdSNU5t7sOcxu3nmMkKzHYNH5mDcFbvL_7-P8H3lGgs8Vf-AO02ZaYsh7Ag5JAIOv642sJ8I5Y0KzuvoJN3e2uQ</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>Cedeno-Laurent, Filiberto</creator><creator>Dimitroff, Charles J</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120201</creationdate><title>Galectin-1 research in T cell immunity: Past, present and future</title><author>Cedeno-Laurent, Filiberto ; Dimitroff, Charles J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c539t-ef15ec7ec876b4bad85b80dbe58a345c6d595a681a132b6d19af8f7286b45afd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Allergy and Immunology</topic><topic>Amino Sugars - immunology</topic><topic>Amino Sugars - metabolism</topic><topic>Animals</topic><topic>Apoptosis - immunology</topic><topic>Biological and medical sciences</topic><topic>Cancer immune evasion</topic><topic>Carbohydrate therapeutics</topic><topic>Cell Survival - immunology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Galectin 1 - chemistry</topic><topic>Galectin 1 - history</topic><topic>Galectin 1 - immunology</topic><topic>Galectin 1 - metabolism</topic><topic>Galectin-1</topic><topic>Galectin-1 ligands</topic><topic>History, 21st Century</topic><topic>Humans</topic><topic>Immunomodulation - immunology</topic><topic>Immunoregulation</topic><topic>Immunotherapy</topic><topic>Inflammation - immunology</topic><topic>Inflammation - metabolism</topic><topic>Inflammation - therapy</topic><topic>Ligands</topic><topic>Lymphocyte Activation - immunology</topic><topic>Mice</topic><topic>Mice, Knockout</topic><topic>Models, Immunological</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - therapy</topic><topic>Recombinant Proteins - immunology</topic><topic>Recombinant Proteins - metabolism</topic><topic>T-Lymphocyte Subsets - immunology</topic><topic>T-Lymphocyte Subsets - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cedeno-Laurent, Filiberto</creatorcontrib><creatorcontrib>Dimitroff, Charles J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical immunology (Orlando, Fla.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cedeno-Laurent, Filiberto</au><au>Dimitroff, Charles J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Galectin-1 research in T cell immunity: Past, present and future</atitle><jtitle>Clinical immunology (Orlando, Fla.)</jtitle><addtitle>Clin Immunol</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>142</volume><issue>2</issue><spage>107</spage><epage>116</epage><pages>107-116</pages><issn>1521-6616</issn><eissn>1521-7035</eissn><coden>CLIIFY</coden><abstract>Abstract Galectin-1 (Gal-1) is one of 15 evolutionarily conserved ß-galactoside-binding proteins that display biologically-diverse activities in pathogenesis of inflammation and cancer. Gal-1 is variably expressed on immune cells and endothelial cells, though is commonly found and secreted at high levels in cancer cells. It induces apoptosis in effector T cells through homodimeric binding of N-acetyllactosamines on membrane glycoproteins (Gal-1 ligands). There is also compelling evidence in models of cancer and autoimmunity that recombinant Gal-1 (rGal-1) can potentiate immunoregulatory function of T cells. Here, we review Gal-1's structural and functional features, while analyzing potential drawbacks and technical difficulties inherent to rGal-1's nature. We also describe new Gal-1 preparations that exhibit dimeric stability and functional activity on T cells, providing renewed excitement for studying Gal-1 efficacy and/or use as anti-inflammatory therapeutics. We lastly summarize strategies targeting the Gal-1–Gal-1 ligand axis to circumvent Gal-1-driven immune escape in cancer and boost anti-tumor immunity.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>22019770</pmid><doi>10.1016/j.clim.2011.09.011</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1521-6616 |
| ispartof | Clinical immunology (Orlando, Fla.), 2012-02, Vol.142 (2), p.107-116 |
| issn | 1521-6616 1521-7035 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3266984 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Allergy and Immunology Amino Sugars - immunology Amino Sugars - metabolism Animals Apoptosis - immunology Biological and medical sciences Cancer immune evasion Carbohydrate therapeutics Cell Survival - immunology Fundamental and applied biological sciences. Psychology Fundamental immunology Galectin 1 - chemistry Galectin 1 - history Galectin 1 - immunology Galectin 1 - metabolism Galectin-1 Galectin-1 ligands History, 21st Century Humans Immunomodulation - immunology Immunoregulation Immunotherapy Inflammation - immunology Inflammation - metabolism Inflammation - therapy Ligands Lymphocyte Activation - immunology Mice Mice, Knockout Models, Immunological Neoplasms - immunology Neoplasms - metabolism Neoplasms - therapy Recombinant Proteins - immunology Recombinant Proteins - metabolism T-Lymphocyte Subsets - immunology T-Lymphocyte Subsets - metabolism |
| title | Galectin-1 research in T cell immunity: Past, present and future |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A54%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Galectin-1%20research%20in%20T%20cell%20immunity:%20Past,%20present%20and%20future&rft.jtitle=Clinical%20immunology%20(Orlando,%20Fla.)&rft.au=Cedeno-Laurent,%20Filiberto&rft.date=2012-02-01&rft.volume=142&rft.issue=2&rft.spage=107&rft.epage=116&rft.pages=107-116&rft.issn=1521-6616&rft.eissn=1521-7035&rft.coden=CLIIFY&rft_id=info:doi/10.1016/j.clim.2011.09.011&rft_dat=%3Cproquest_pubme%3E920230821%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=920230821&rft_id=info:pmid/22019770&rft_els_id=S1521661611002804&rfr_iscdi=true |